PS21: FDA's CDER and CBER PDUFA VII Guidance on Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products: Development and Implementation

Under the Prescription Drug User Fee Act (PDUFA) VII commitments, the FDA has developed draft guidance on the Use of Bayesian Methodology in Clinical Trials of Drugs and Biologics. This guidance aims to provide clarity on expectations for the regulatory use of Bayesian methods, focusing specifically on their use to support primary inference in clinical trials for demonstrating drug and biological product effectiveness and safety. This session will provide attendees with insights into the regulatory framework and practical implementation considerations for Bayesian approaches in pharmaceutical development. This session features two complementary perspectives. The first presentation will be delivered by an FDA representative who participated in the guidance development process, providing insights into the regulatory rationale, scope, and expectations outlined in the draft guidance. Key topics will include perspectives on Bayesian methodologies, considerations for trial design and analysis, and potential expectations for submission documentation and justification. The second presentation will feature an industry representative who will address practical implementation challenges and opportunities from a pharmaceutical development perspective. This presentation will explore how industry can leverage Bayesian methods to enhance clinical trial efficiency and address regulatory requirements. Following the presentations, a moderated panel discussion will address key implementation questions, best practices for successful Bayesian trial design, and regulatory submission strategies. The session will conclude with an audience question and answer segment, providing attendees the opportunity to engage directly with both regulatory and industry experts on specific technical, procedural, and strategic questions related to Bayesian methodology implementation. Attendees will gain practical understanding of potential expectations for Bayesian methods, industry perspectives on implementation challenges, and actionable insights for incorporating Bayesian approaches into their clinical development programs. As the pharmaceutical industry increasingly adopts innovative statistical methodologies, this session addresses a critical knowledge gap by providing clarity on expectations and practical implementation strategies for Bayesian methods in clinical trials, supporting more efficient and scientifically robust drug development processes.